STOCK TITAN

Evaxion 6-K incorporates press release into S-8, F-1 and F-3

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K announcing that it provided a press release titled “Evaxion announce 2026 financial calendar.” The report is incorporated by reference into the company’s existing registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files, allowing the press release to form part of those registrations going forward. The press release is attached as Exhibit 99.1.

Positive

  • None.

Negative

  • None.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]


INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 12, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion announce 2026 financial calendar". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number Description
   
99.1 Evaxion announce 2026 financial calendar


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Evaxion A/S
   (Registrant)
    
   
Date: November 12, 2025 By:/s/ Birgitte Rønø    
   Birgitte Rønø
   Interim Chief Executive Officer
   

FAQ

What did EVAX file?

Evaxion A/S filed a Form 6-K as a report of a foreign private issuer.

What was furnished with the 6-K by EVAX?

A press release titled “Evaxion announce 2026 financial calendar” as Exhibit 99.1.

Is the 6-K incorporated by reference into EVAX registrations?

Yes. It is incorporated by reference into Form S-8 (333-255064), multiple Form F-1 files, and Form F-3 files including 333-265132 and 333-285778.

Which annual report form does EVAX use?

The company files annual reports under Form 20-F.

Where is the press release in the filing?

It is attached as Exhibit 99.1 to the Form 6-K.
Evaxion AS

NASDAQ:EVAX

EVAX Rankings

EVAX Latest News

EVAX Latest SEC Filings

EVAX Stock Data

39.78M
6.88M
23.07%
6.82%
1.91%
Biotechnology
Healthcare
Link
Denmark
Horsholm